Morgan Stanley analyst Alex Straton lowered the firm’s price target on Bath & Body Works to $40 from $41 and keeps an Overweight rating on the shares after updating the firm’s estimates post-Q2 results.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBWI:
- Bath & Body Works to hire over 30,000 seasonal associates ahead of holidays
- Positive Outlook on Bath & Body Works Amid Strategic Growth and Attractive Valuation
- Bath & Body Works Earnings Call Highlights Strong Growth
- Bath & Body Works: Strong Financial Performance and Strategic Initiatives Justify Buy Rating
- Cautious Optimism for Bath & Body Works: Buy Rating Amidst Challenges and Strategic Potential